Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEBULA-1: Efimosfermin alfa in compensated cirrhosis due to MASH
jRCT2041260084Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis comparing Efimosfermin alfa with Placebo (2 arms). Primary endpoint: Time to composite liver-related clinical outcome. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
efimosfermin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on jRCT2041260084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260084.